



MSBase Foundation Ltd
Central Clinical School
Level 6, the Alfred Centre
99 Commercial Rd
Melbourne VIC 3004
Australia

15.11.2020

Dear HRA & Devolved Nation Research Governance Assessors/Reviewers

Re: MSBase Registry (IRAS:286711) IRAS categorisation and exemption from study-wide governance assessment and C&C processing.

The MSBase Registry is a longitudinal, strictly observational Multiple Sclerosis database open to all practicing Neurologists and their teams, worldwide. In collaboration with participating Neurologists, the MSBase Registry has established a unique, web-based platform dedicated to sharing, tracking and evaluating outcomes data in Multiple Sclerosis (MS) and other Central Nervous System (CNS) demyelinating diseases. In particular, MSBase aims to advance multicentre, multi-national epidemiological and outcomes research by providing a freely accessible resource to compile, combine, compare and analyse large datasets.

As per the application documentation, the MSBase Registry is hosted outside of the UK in Australia. I have been previously advised by the HRA enquiry line (see correspondence enclosed) that, under Section 11 of the Standard Operating Procedures for Research ethics Committees, MSBase cannot therefore undergo a voluntary UK REC review as a research database/registry. As directed, in order to enable review of the arrangements for recruitment of patients via the NHS (rather than the registry management arrangements), the IRAS application has been submitted as a “*Study limited to working with data (specific project only)*”.

However, as MSBase is a research registry, it falls outside of the scope of the UK Policy Framework for Health and Social Care Research and, as such, does not require governance assessment beyond REC review. For the same reason, the project does not require confirmation of C&C or governance permissions at participating sites and so no OID or SoECAT have been provided with this submission. A cover letter to all participating sites (enclosed) will clarify this and explain the inconsistency in IRAS study type which was selected only in order to enable REC review of the recruitment arrangements for NHS/HSC patients as registry participants.

Please do not hesitate to contact me to discuss any aspect of this submission.

Yours sincerely

A handwritten signature in black ink that reads "Orla Gray". The signature is written in a cursive style with a long horizontal stroke at the end of the name.

Dr Orla Gray

Consultant Neurologist/U.K. Chief Investigator